Kymera Therapeutics to Participate in Upcoming June Investor Conferences
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company specializing in targeted protein degradation (TPD), announced its participation in the Jefferies 2024 Global Healthcare Conference and the Goldman Sachs 45th Annual Global Healthcare Conference. The Jefferies conference will take place in New York on June 5 at 11:30 a.m. ET, while the Goldman Sachs event will be held in Miami on June 11 at 2:40 p.m. ET. Both events will feature live webcasts, accessible through Kymera's website, with replays available post-events.
- Participation in major healthcare conferences can increase investor visibility and confidence.
- Live webcasts and archived replays provide transparency and accessibility for stakeholders.
- No new financial or clinical data were disclosed in the announcement.
- The PR does not mention any upcoming milestones or significant business developments.
WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:
- Jefferies 2024 Global Healthcare Conference in New York, NY on June 5 at 11:30 a.m. ET; and
- Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL on June 11 at 2:40 p.m. ET.
Live webcasts of the presentations will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. Replays of the webcasts will be archived and available following the events.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X (previously Twitter) or LinkedIn.
Investor and Media Contact:
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300
FAQ
What conferences will Kymera Therapeutics attend in June 2024?
When is Kymera Therapeutics presenting at the Jefferies 2024 Global Healthcare Conference?
Where can I watch Kymera Therapeutics' presentations at the June investor conferences?
Will replays of Kymera Therapeutics' conference presentations be available?
What is the ticker symbol for Kymera Therapeutics?
